Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI versus ARB for proteinuria reduction in diabetic chronic kidney disease
NL-OMON45510Phase 3Withdrawn
- Sponsor
- Erasmus MC
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sacubitril + valsartan and valsartan in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in 24-hour proteinuria. Planned start Mar 2017; status: withdrawn.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON45510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45510.